Clinical trials: Tamsulosin
Prostatic Hyperplasia
A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State
This study will be an open-label, randomized, single dose, three way partial crossover study in healthy male subjects. The aim of the study is to evaluate bioequivalence of a fixed dose combination (FDC) capsule of dutasteride…
- Trial name
- NCT00537654
- Testing
- Treatment sequence A, Treatment sequence B, Treatment sequence C
- Where
- 2 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.
Benign prostatic hyperplasia (BPH) is an age-related progressive condition of the prostate gland that results in an increase in prostate size.
- Trial name
- KALLIRROI (NCT06528613)
- Where
- 6 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Prostatic Hyperplasia
Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.
This study aims to determine the relative bioavailability of tamsulosin hydrochloride in a fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg) relative to co-administration of dutasteride…
- Trial name
- ARI115707 (NCT01471678)
- Testing
- Dutasteride (0.5mg), FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg), Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)
- Where
- Australia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)
Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control.
- Trial name
- NCT07619105
- Testing
- Vesomni
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Korea, Inc.
Healthy Volunteer Male Subjects
A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions
The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg…
- Trial name
- NCT07156916
- Testing
- Tamsulosin (0.4 mg/j)
- Where
- Armenia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Berlin-Chemie AG Menarini Group
Erectile Dysfunction, Benign Prostatic Hyperplasia
Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin
We investigate the potential pharmacokinetic drug-drug interaction between Tadalafil and Tamsulosin in healthy male volunteers who receive Tadalafil alone, Tamsulosin alone, and both together in a 3 period repeatedly.
- Trial name
- NCT02239484
- Testing
- Tadalafil, Tamsulosin, Tadalafil + Tamsulosin
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
BPH, Benign Prostatic Hyperplasia
An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
In this study, BPH patients visited the institutions during the study period and the effectiveness and safety of the treatment of Tamsulosin(Hanmi Tams® Capsule) in real-practice.
- Trial name
- NCT05422677
- Testing
- Hanmi Tams® Capsule
- Where
- South Korea
- Volunteers
- 4,698 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Erectile Dysfunction
Phase I Study to Investigate the Drug Interaction After Oral Administration of Tamsulosin and SK3530
To assess the pharamcodynamic effects of coadministrated SK3530(PDE5 inhibitor) and tamsulosin, phase I study in healthy volunteers was designed.
- Trial name
- NCT00489606
- Testing
- SK3530
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Prostatic Hyperplasia
SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin
It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the healthy male volunteers under fasting conditions receive, in each period, the test formulation…
- Trial name
- NCT01262989
- Testing
- Test formulation, Reference formulation
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
EC905, Pharmacokinetics
A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin
A study to assess the amount of drug in the blood of young to middle aged, healthy, male subjects after they received the final formulation of EC905 compared to solifenacin (Vesicare®) and tamsulosin OCAS (Omnic OCAS®).
- Conditions
- EC905, Pharmacokinetics, Healthy Subjects
- Trial name
- NCT01953887
- Testing
- EC905, solifenacin, tamsulosin
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
Bioequivalence Study of Tamsulosin 0.4 mg Sustained Release Film-coated Tablets
This study was an open-label, randomized, single-dose, four-period, two-sequence, fully replicate study under fasting conditions which included 28 healthy adult male subjects.
- Trial name
- NCT06558032
- Testing
- Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia), Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)
- Where
- Indonesia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
Benign Prostatic Hyperplasia
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
This study is designed to compare safety and efficacy of monotherapy finasteride to combination therapy (finasteride and tamsulosin) in Asian men with benign prostatic hyperplasia (BPH) who are at least 50 years of age or older.
- Trial name
- NCT01534351
- Testing
- Finasteride, Tamsulosin
- Volunteers
- 1 people
- Sponsor
- Merck Sharp & Dohme LLC
Erectile Dysfunction
Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin
The purpose of this study is to see if avanafil causes any changes in blood pressure and pulse rate when taken with doxazosin or tamsulosin.
- Trial name
- NCT01100021
- Testing
- Tamsulosin and avanafil, Doxazosin and avanafil
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Prostatic Hyperplasia
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
The primary objective of this study is to determine the bioavailability of a FDC capsule formulation of dutasteride and tamsulosin hydrochloride (0.5 milligram [mg]/0.2 mg) relative to coadministration of one dutasteride 0.5 mg…
- Trial name
- NCT02509104
- Testing
- FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions
The objective of this study is to evaluate the comparative bioavailability between tamsulosin hydrochloride 0.4 mg capsules (Manufactured by Teva Pharmaceutical Industries Ltd.; distributed by Teva Pharmaceuticals USA) and…
- Trial name
- NCT01149733
- Testing
- Tamsulosin
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Prostatic Hyperplasia
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
This study will be an open-label, randomized, single dose, two-period crossover study to determine the bioavailability of a fixed dose combination capsule formulation of dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg)…
- Trial name
- ARI114694 (NCT01254071)
- Testing
- Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
- Where
- Australia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cardiovascular, Healthy Subjects
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
The study aims to compare blood pressure and pulse in male healthy subjects taking mirabegron and tamsulosin both alone and in combination.
- Conditions
- Cardiovascular, Healthy Subjects, Pharmacokinetics
- Trial name
- NCT01489696
- Testing
- mirabegron, tamsulosin
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
LUTS, Benign Prostatic Hyperplasia
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02180997
- Testing
- Tamsulosin, Solifenacin, Tamsulosin and solifenacin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Healthy Volunteers, Male
A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions
The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0,4 mg…
- Trial name
- NCT07091669
- Testing
- Tamsulosin (0.4 mg/j)
- Where
- Armenia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Berlin-Chemie AG Menarini Group
Healthy, Pharmacokinetics of Tamsulosin Hydrochloride
A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy Subjects
The purpose of this study is to investigate the relative bioavailability of two types of prolonged release formulation of tamsulosin hydrochloride in Chinese healthy subjects. The safety of tamsulosin formulation is also compared.
- Trial name
- NCT02138773
- Testing
- Tamsulosin formulation-A, Tamsulosin formulation-B
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma China, Inc.